RxDoctor Payments Data

Alexandre Alexeyenko, MD

Internal Medicine · Lynn, MANPI 1568464279

Payments from drug & device makers

$769in general payments, 2019–2025

Across 37 payments — averaging $20.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$232
  • Boehringer Ingelheim$170
  • Eisai Inc.$52
  • Lilly USA, LLC$49
  • AbbVie$38
  • Otsuka America Pharmaceutical, Inc.$38
  • plus $191 from 9 others

What the payments were for

  • Food & beverage$769100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$769 in reported general payments places this provider in the 80th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$42,018
Medicare patients
138
Services billed
679

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin306$184,834
TrulicityDulaglutide166$175,360
EliquisApixaban259$157,836
XareltoRivaroxaban156$100,083
OzempicSemaglutide82$86,592
FarxigaDapagliflozin Propanediol103$64,353
JanuviaSitagliptin Phosphate86$48,519
LinzessLinaclotide87$46,641
TradjentaLinagliptin80$42,086
DapagliflozinDapagliflozin Propanediol62$33,698
CreonLipase/Protease/Amylase68$29,489
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$28,309
Droxidopa13$28,292
MounjaroTirzepatide17$24,909
Rosuvastatin Calcium1,736$20,743

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$170$234,010400 claims
Lilly USA, LLCTrulicity, Mounjaro$49$200,269183 claims
PfizerEliquis$13$157,836259 claims
Novo NordiskOzempic, Rybelsus$36$106,040102 claims
AbbVieLinzess, Creon$38$76,130155 claims
AstraZenecaFarxiga, Crestor$232$71,716128 claims
GSKTrelegy Ellipta, Breo Ellipta$16$39,85466 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Lynn

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →